Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin (Q35034528)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin |
scientific article |
Statements
1 reference
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin (English)
1 reference
Hagop Kantarjian
1 reference
Srdan Verstovsek
1 reference
Jorge Cortes
1 reference
Susan O'Brien
1 reference
Farhad Ravandi
1 reference
Guillermo Garcia-Manero
1 reference
Jenny Shan
1 reference
Alfonso Quintás-Cardama
1 reference
Dan Jones
1 reference
Charles Koller
1 reference
Jody Hiteshew
1 reference
30 September 2010
1 reference
1 reference
117
1 reference
3
1 reference
572-580
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference